Second- and third-generation ALK inhibitors for non-small cell lung cancer

被引：0
|
作者：
Jingjing Wu
John Savooji
Delong Liu
机构：
[1] The First Affiliated Hospital of Zhengzhou University,Department of Oncology
[2] Westchester Medical Center and New York Medical College,Department of Medicine
来源：
Journal of Hematology & Oncology | / 9卷
关键词：
Brain Metastasis; Pemetrexed; Anaplastic Lymphoma Kinase; Anaplastic Large Cell Lymphoma; Crizotinib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Crizotinib as the first-generation ALK inhibitor has shown significant activity in ALK-mutated non-small cell lung cancer (NSCLC). Second- and third-generation ALK inhibitors are entering clinical applications for ALK+ NSCLC. In addition, a third-generation ALK inhibitor, lorlatinib (PF-06463922), was reported to resensitize NSCLC to crizotinib. This review provided a summary of clinical development of alectinib, ceritinib, brigatinib (AP26113), and lorlatinib.
引用
收藏
相关论文
共 50 条
  • [21] Third-Generation Tyrosine Kinase inhibitors Targeting epidermal Growth Factor Receptor Mutations in non-Small Cell Lung Cancer
    Barnes, Tristan A.
    O'Kane, Grainne M.
    Vincent, Mark David
    Leighl, Natasha B.
    FRONTIERS IN ONCOLOGY, 2017, 7
  • [22] Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
    Shuhang Wang
    Shundong Cang
    Delong Liu
    Journal of Hematology & Oncology, 9
  • [23] Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
    Wang, Shuhang
    Cang, Shundong
    Liu, Delong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9
  • [24] Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells
    Dong, Xuyuan
    Fernandez-Salas, Ester
    Li, Enxiao
    Wang, Shaomeng
    NEOPLASIA, 2016, 18 (03): : 162 - 171
  • [25] Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer
    de Castria, Tiago B.
    da Silva, Edina M. K.
    Gois, Aecio F. T.
    Riera, Rachel
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (08):
  • [26] Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer
    Vasconcellos, Vitor F.
    Marta, Guilherme N.
    da Silva, Edina M. K.
    Gois, Aecio F. T.
    de Castria, Tiago B.
    Riera, Rachel
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2020, (01):
  • [27] Adverse effects and associated costs with second- and third-line therapies for non-small cell lung cancer
    Ye, X.
    Darkow, T.
    Reyes, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [28] Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer
    de Marinisa, Filippo
    Grossi, Francesco
    ONCOLOGIST, 2008, 13 : 14 - 20
  • [29] Tackling ALK in non-small cell lung cancer: the role of novel inhibitors
    Facchinetti, Francesco
    Tiseo, Marcello
    Di Maio, Massimo
    Graziano, Paolo
    Bria, Emilio
    Rossi, Giulio
    Novello, Silvia
    TRANSLATIONAL LUNG CANCER RESEARCH, 2016, 5 (03) : 301 - 321
  • [30] Three Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Similarities and Differences
    Chen, Ling
    Zhou, Yangqingqing
    Gan, Chaosheng
    Wang, XiaoLi
    Liu, Yihui
    Dong, Chunhui
    He, Ruiyuan
    Yang, Jin
    CANCER INVESTIGATION, 2022, 40 (07) : 590 - 603
12345